Coordinating the collection and delivery of cells for cell and gene therapy developers begins long before the first patient or donor is collected. Our Be The Match BioTherapies® Collection Network Liaison team works with cell and gene therapy clients to understand their needs. Then, they use established, standardized approaches to onboard, audit and train the…
Autologous and allogeneic CAR-T therapies continue to hold significant promise for patients. But with that potential comes challenges, as more CAR-T therapies enter clinical trials and commercialization. Some are universal to both autologous CAR-T and allogeneic CAR-T, but each has its unique obstacles, too. Abby McDonald, PhD, supervises the Solutions Development team for Be The…
For cell and gene therapy companies developing allogeneic therapies, including allogeneic CAR-T or T-cell immunotherapies, getting high-quality starting material from healthy adult donors is critical to the success of their therapies. But, what is it like to be the allogeneic donors who get the call asking them to be volunteer donors? And why would they…
What if you could shorten the time it takes to activate apheresis and cell collection sites to begin collecting starting material for your cell or gene therapy and simultaneously create efficiencies for those sites? A standardized quality system audit (QSA) program, like the Quality System Audit Program (QSAP) offered by Be The Match BioTherapies®, helps…
The UCLA Health Hematologic Malignancy/Stem Cell Transplant Program has been a pioneer in providing cell therapies to patients with hematologic cancers and disorders. In 2015, UCLA began participating in multisite clinical trials for CAR-T therapy and was one of the first centers in the nation to offer both FDA-approved CAR-T therapies, Kymriah® and Yescarta®. As…
Ensuring cell collection centers and cell therapy labs are meeting FDA regulatory requirements and providing high-quality starting material for your cell or gene therapy is critical to your therapy’s success. As the industry continues to rapidly advance, it is becoming more critical to integrate process efficiencies wherever possible. There is a solution: using an established…
A well-designed cell and gene therapy supply chain is critical to patient care. Managing the cell therapy supply chain is a mission-critical industry skill. Yet, no matter how well designed your supply chain is, human-based therapies are subject to variability at each stage of delivery. At Be The Match BioTherapies®, we make sure our team…
This has been a landmark year for the cell and gene therapy industry. It’s also been an exciting year for Be The Match BioTherapies®, as we’ve forged new partnerships and expanded our international presence. We highlight a few key efforts below as we look forward to the year ahead. The push toward cell and gene…
Amy Hines, BSN, RN, oversees the Be The Match BioTherapies® Collection Network, which includes apheresis centers, marrow collection centers and cell therapy labs. She talked to us about some of the challenges the Network is facing, how Be The Match BioTherapies can help build efficiencies and how the organization plans to save more lives internationally.…